We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Announces Appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer

    GAITHERSBURG, Md. & BOSTON--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer, responsible for leading clinicalRead More

  • Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company

    Acquisition Advances Sensei’s Core Capabilities in Immunology and Antibody Engineering by Supercharging its ImmunoPhage™ Platform GAITHERSBURG, Md. & BOSTON--( BUSINESS WIRE )-- Sensei Biotherapeutics , Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies,Read More

  • Sensei Biotherapeutics Appoints Robert Pierce, M.D., as Chief Scientific Officer

    Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team GAITHERSBURG, Md. & BOSTON--( BUSINESS WIRE )-- Sensei Biotherapeutics , Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced theRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Announces Appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer

    GAITHERSBURG, Md. & BOSTON--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer, responsible for leading clinicalRead More

  • Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company

    Acquisition Advances Sensei’s Core Capabilities in Immunology and Antibody Engineering by Supercharging its ImmunoPhage™ Platform GAITHERSBURG, Md. & BOSTON--( BUSINESS WIRE )-- Sensei Biotherapeutics , Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies,Read More

  • Sensei Biotherapeutics Appoints Robert Pierce, M.D., as Chief Scientific Officer

    Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team GAITHERSBURG, Md. & BOSTON--( BUSINESS WIRE )-- Sensei Biotherapeutics , Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced theRead More

Signup For Update

sign up for newsletter and get the latest update